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Decrease of GABAergic transmission has been proposed to improve memory functions. Indeed, inverse agonists selective for α5
GABA-A-benzodiazepine receptors (α5IA) have promnesiant activity. Interestingly, we have recently shown that α5IA can rescue
cognitive deﬁcits in Ts65Dn mice, a Down syndrome mouse model with altered GABAergic transmission. Here, we studied the
impact of chronic treatment with α5IA on gene expression in the hippocampus of Ts65Dn and control euploid mice after being
trained in the Morris water maze task. In euploid mice, chronic treatment with α5IA increased IEGs expression, particularly of
c-Fos and Arc genes. In Ts65Dn mice, deﬁcits of IEGs activation were completely rescued after treatment with α5IA. In addition,
normalization of Sod1 overexpression in Ts65Dn mice after α5IA treatment was observed. IEG expression regulation after α5IA
treatment following behavioral stimulation could be a contributing factor for both the general promnesiant activity of α5IA and
its rescuing eﬀect in Ts65Dn mice alongside signaling cascades that are critical for memory consolidation and cognition.
1.Introduction
Down syndrome (DS) aﬀects 0.45% of human conceptions
[1] and is the ﬁrst cause of mental retardation. This disorder
is induced by total or partial trisomy of human chromo-
some 21 (HSA21) that delays both physical and mental
development of aﬀected children. In particular, cognitive
skills, including learning and memory functions, are severely
impaired in DS subjects.
Although being the focus of intense research activity
[2, 3], attempts at developing treatments for counteracting
cognitive defects in DS patients have not yet been successful.
Since ﬁfteen years, DS animal models have been engi-
neered to mimic DS physiopathogeny. Ts65Dn mice [4],
one of the most studied DS models, have 167 three-copy
genes corresponding to more than half of the genes from
HSA21. These mice develop gradual learning and memory
impairments when compared to euploid animals (for review,
see [5]) in conjunction with morphological anomalies. In
addition, Ts65Dn mice show abnormal synaptic plasticity as
exempliﬁed by long-term potentiation (LTP) deﬁcits [6].
Data from recent years strongly suggest that changes in
LTP and associated learning and memory function in DS
mice might result from an imbalance between excitatory and2 Advances in Pharmacological Sciences
inhibitory neurotransmission. More precisely, it has been
demonstrated that increased GABAergic activity in the brain
of Ts65Dn mice could be responsible for altered cognitive
phenotypes [7, 8], opening new avenues for therapeutic
opportunities. Treatments relying on GABA-A antagonists
such as picrotoxin and pentylenetetrazole (PTZ) have indeed
rescued deﬁcits in DS mice; GABA-A antagonists can restore
normal LTP [8] and also normalize cognitive phenotypes in
learning tests such as the novel object recognition [9]a n d
Morris water maze [10]. Altogether, these studies suggest the
potential use of GABA antagonists for stimulating cognitive
performances in DS subjects. However, it is known that such
drugsalsohaveconvulsanteﬀectswhichdeﬁnitivelypreclude
their use as cognitive enhancers in humans.
As an alternative to GABA-A antagonists, GABA-A
inverse agonists such as β-carbolines acting at the benzodi-
azepine recognition site decrease the eﬃcacy of GABAergic
transmission and have promnesiant eﬀects [11–14]. Their
use in humans is, however, hampered by their convul-
sant/proconvulsant and anxiogenic side eﬀects [15, 16].
It is nonetheless assumed that various pharmacological
proﬁles can be obtained using ligands with speciﬁc aﬃnities
for the diﬀerent α1, α2, α3, or α5 benzodiazepine receptor
subtypes [17] that are unevenly distributed in the brain
[18–20]. It is known that the α5 subunit-containing recep-
tors are largely expressed in the hippocampus [21, 22], a
brain region involved in learning and memory processes
that is dysfunctional in DS individuals [23, 24]. In mice,
invalidation or mutation of the gene coding for the α5
subunit potentiate synaptic plasticity [25] and concurrently
improve cognitive performances [25–27] without inducing
anxiogenic or proconvulsant/convulsant side eﬀects [28–32].
Recently, we demonstrated that acute and chronic treatment
with an α5-selective inverse agonist, and referred to herein
as compound α5IA, initially developed by Merck Sharp and
Dohme Research Laboratories [33, 34] can restore cognitive
deﬁcits in a DS mouse model [35]. We further showed that
following treatment with α5IA, the immediate early gene
(IEG) product Fos is selectively increased in brain regions
involved in learning and memory in control and DS mice
[35].
In order to obtain insights into gene regulation pathways
involved in the pharmacological eﬀect of α5IA, we studied
gene expression proﬁles in hippocampi of euploids and
Ts65Dn mice behaviorally exposed to the Morris water maze
(MWM) task, and treated or not with α5IA. We found
that chronic treatment with α5IA globally increases the
expression of IEGs and in particular of c-Fos and Arc. These
eﬀects could be related to the memory-enhancing properties
classically described for α5IA [28–32].
InDownsyndromemice,weobservedanabnormallylow
level of IEG induction after behavioral stimulation. In addi-
tion,somethree-copygenesweresigniﬁcantlyoverexpressed,
including Sod1 gene. Chronic treatment of Ts65Dn mice
with α5IA normalized the expression level of Sod1 and in
parallelrestoredaphysiologicallevelofIEGsexpression.This
double-action mode can explain the rescuing eﬀect observed
following α5IA treatment in DS mice.
2.MaterialandMethods
2.1. Animals. Male mice were produced at the Intragene
resource center (TAAM, CNRS UPS44 Orl´ eans, France) and
bred on a mixed genetic background B6C3 B ,d e r i v e d
from C57BL/6J (B6) and a congenic inbred line C3H/HeH
for the BALB/c wild-type Pde6b allele [36], thus avoid-
ing retinal degeneration and impaired visual acuity. On
this background, Ts65Dn mice showed similar behavioral
phenotypes when compared to the original Ts65Dn line
(AD and YH, personal communication; see also [37]). Mice
were acclimated in our animal facility for at least 2 weeks
before initiating behavioral testing. All experiments were
conductedinaccordancewiththeethicalstandardsofFrench
and European regulations (European Communities Council
Directive of 24 November 1986). A total number of 24 mice
(12 Ts65Dn and 12 euploid mice) were behaviorally trained
in the MWM task. Only a subset of these animals (7 and 10-
11 mice per genotype for microarray and QPCR analysis,
resp.) were processed for the molecular biology analysis
described in the present work, (Figure 1).
2.2. α5IA Synthesis and Formulation. The drug used is 3-(5-
methylisoxazol-3-yl)-6-(1-methyl-1,2,3-triazol-4-yl)methy-
loxy-1,2,4-triazolo[3,4-a]phthalazine (α5IA). It was synthe-
sized by Orga-Link SARL (Magny-les-Hameaux, France),
according to Sternfeld and collaborators [34]. The hydro-
chloride salt was prepared by dissolving the base in hot
ethanol and adding a solution of 5% hydrochloric acid in
ethanoluntilthesolutionwasslightlyacidic.Uponcooling,a
precipitate formed which was collected by ﬁltration, washed
with cold ethanol, and dried.
The HCl salt of α5IA was solubilized in a mixture of
DMSO,Cremophor El (BASF, Ludwigshafen,Germany),and
hypotonic water (ProAmp) (10:15:75). α5IA or vehicle
(solubilization solution) was injected intraperitoneally (i.p.)
at 5mg/kg [35].
2.3. Morris Water Maze. Cognitive stimulation was per-
formed during 12 consecutive days in the MWM as previ-
ously described [35]. In brief, training consisted in a goal-
location task in a pool (2–4 learning trials per daily sessions).
Euploid and Ts65Dn mice were injected each day with either
vehicleorα5IA(6micepergroup),30minbeforestartingthe
session. Distance travelled to ﬁnd the platform has been used
as learning index. We compared the performances of vehicle-
treated Ts65Dn mice to the 3 other groups (α5IA-treated
Ts65Dn mice, vehicle-treated euploids, and α5IA-treated
euploids) using Student’s t-tests. Statistical signiﬁcance was
set to a P value <0.05.
2.4. cRNA Probe Preparation and Hybridization. Twenty ﬁve
min following the last MWM training session, animals were
sacriﬁced, and their brains were extracted and processed
for gene expression proﬁling. Total RNAs were obtained
from frozen individual hippocampi and treated with DNAse
using NucleoSpin RNA II kit (Macherey Nagel, France) in
accordance with the manufacturer’s protocol. The qualityAdvances in Pharmacological Sciences 3
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Figure 1: Experimental design used for the genomic studies: microarray and QPCR.
and quantity of each RNA preparation were assessed on
the Agilent 2100 Bioanalyzer with RNA 6000 NanoChips
(Agilent Technologies).
Hundred ng of each RNA were ampliﬁed and labelled
with Cy3 using the Low Imput Quick Amp labeling kit
(Agilent Technologies) according to the manufacturer’s
instructions. After puriﬁcation and quantiﬁcation on a
Nanoview (ThermoFisher Scientiﬁc), 2μgo fe a c hC y 3 -
cRNA were hybridized overnight on Whole Mouse Genome
4 × 44K v1 Microarrays(Agilent Technologies) accordingto
the manufacturer’s instructions.
2.5. Microarray Expression Data Analysis. Microarrays data
were acquired on an Innoscan 900 (Innopsys, France) with
ar e s o l u t i o no f2μm and analyzed with Mapix 5.0.0 software
(Innopsys, France). For each array, raw data consisted of the
median feature intensity and background feature intensity
(F-B) at wavelength 532nm. These raw data were log2
transformed and quantile normalized under the R freeware
(http://www.r-project.org/). Analysis of variance (ANOVA)
with two main factors, Genotype (Ts65Dn versus euploid)
and Treatment (α5IA versus vehicle), was then performed on
the normalized data using the software MeV 4.6.2 (http://
www.tm4.org/mev/). Gene ontology (GO) category enrich-
ment analysis was realized using the web-based GOrilla
application (http://cbl-gorilla.cs.technion.ac.il/). Statistical
signiﬁcance was set to a P value <0.05.
2.6. Real-Time Quantitative PCR. RNAs from dissected
hippocampi (500ng) were individually reverse transcribed
into cDNAs overnight at 37◦C using the Verso cDNA kit
(ThermoFisher Scientiﬁc, Waltham, USA) according to the
manufacturer’s instructions. qPCR assays were performed
in a Lightcycler 480 System (Roche), in the presence of
200nM of each primer: (c-Fos 5 agggagctgacagatacactc-
c3  forward and 5 tgcaacgcagacttctcatc3  reverse; Homer1
5 gatggagctgaccagtaccc3  forward and 5 tggtgtcaaaggaga-
ctgaaga3  reverse; Ifnar2 5 ggacagcgttaggaagaagc3  forward
and 5 tggaagtaagtctctaaggacaaatg3  reverse; Egr2 5 ctacccggt-
ggaagacctc3  forward and 5 aatgttgatcatgccatctcc3  reverse;
Bdnf 5 agtctccaggacagcaaagc3  forward and 5 tgcaaccgaagt-
atgaaataacc3  reverse; Arc 5 ggtgagctgaagccacaaat3  forward
and 5 ttcactggtatgaatcactgctg3  reverse; Sod1 5 caggacctc-
attttaatcctcac3  forward and 5 tgcccaggtctccaacat3  reverse;
pPib 5 ttcttcataaccacagtcaagacc3  forward and 5 accttccgt-
accacatccat3  reverse for normalization), 100nM of speciﬁc
hydrolysis probe (designed with Universal Probe Library,
Roche Applied Science) and 1X Lightcycler 480 Probes
Master mix (Roche, France) and normalized using the
Lightcycler480SW1.5software.Datawereanalyzedusingan
analysis of variance (ANOVA) with two main factors: geno-
type (Ts65Dn versus euploid) and treatment (α5IA versus
vehicle), and Fisher’s post hoc complementary analysis was
carried out when required by the experimental design to
assess complementary statistical eﬀects. Pearson correlation
coeﬃcients between IEGs expression and behavioral data
(mean distance travelled during the ﬁrst three days trial of
theMWMtask)werecalculated.Allanalyseswereperformed
using Statistica v6 (StatSoft, Inc., Tulsa, Okla, USA) or
GraphPad Prism (GraphPad Software, La Jolla, Calif, USA)
softwares. Statistical signiﬁcance was set to a P value <0.05.
3. Results
3.1. Gene Expression Proﬁles after Treatment with α5IA in
Euploid and Ts65Dn Mice Hippocampi. We showed previ-
ously that Ts65Dn mice are impaired in the MWM task and
thattheirlearningproﬁciencycanberestoredfollowingα5IA
treatment [35]. In the present study, mice were trained in
the MWM task using a similar protocol and treated daily
withα5IA(5mg/kg).Behavioraldatawereanalyzedalthough
the number of animals was small (5 or 6 per group) and
precluded any robust statistical analysis (ANOVA). During
the three ﬁrst training sessions, vehicle-treated Ts65Dn mice
travelled a longer distance to ﬁnd the platform as compared
to α5IA-treated Ts65Dn mice or euploid mice treated with
vehicle or α5IA (t16 = 7.23; P = .016; Figure 2). Thus,
as previously described in [35], we showed that behavioral
deﬁcit of the Ts54Dn mice in the MWM task was recovered
following α5IA treatment. Twenty ﬁve minutes after com-
pletion of this long-term behavioral stimulation (12 days),4 Advances in Pharmacological Sciences
Table 1: Analysis of variance (ANOVA) of microarray data: genotype (Euploids versus Ts65Dn mice) and treatment (Vehicle versus α5IA-
treated) were the two main factors. Three-copy genes and IEGs were analyzed separately.
Analysis of variance (ANOVA) of microarray data
Total Genotype-modulated genes Treatment-modulated genes Interaction-modulated genes
All genes 13024 848 781 1260
3N genes 56 6 3 5
Genes GART, Ifnar-2, Kcnj6, Itsn1, Hlcs,a n d
Sod1 App, Kcnj6,a n dSod1 Cbr1, Gabpa, 4931408A02Rik,
Hmngn1,a n dPcp4
IEGs and BDNF 16 5(∗∗∗)3 ( ∗)1
Genes BDNF, Cox2, Homer1, GS2,a n dArc Fos, Egr2,a n dBDNF BDNF
Behavioral data
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Figure 2: Eﬀects of α5IA treatment in Ts65Dn mice trained in the
MWM task. TS65Dn mice had impaired performance in the MWM
task (comparison with other groups: P<. 025). This deﬁcit was
rescued by treatment with α5IA.
mice were sacriﬁced and their hippocampi dissected. RNAs
wereextractedandampliﬁed,labeledusinginvitrotranscrip-
tion, and then hybridized on microarrays.
Among 41,000 genes present on the microarray, 13,024
were found to be expressed. Data were normalized and
analyzed using ANOVA with two factors: genotype and
treatment(Table 1). We found an eﬀect of genotype (euploid
versus Ts65Dn) on 848 genes representing 4.52% of whole
genes expressed, an eﬀect of treatment (vehicle versus α5IA
5mg/kg) on 781 genes (4.17%) and a genotype-treatment
interaction eﬀect on 1,260 genes (6.73%). Principal compo-
nent analysis (PCA) using all the genes expressed did not
reveal any segregation of animal groups (data not shown),
indicating that genotype and treatment did not globally
aﬀect expression proﬁles. Among the diﬀerentially expressed
genes, we searched for enrichment of genes belonging to
particular gene ontology (GO) categories. As shown in
Table 2, 17 and 19 GO categories were signiﬁcantly enriched
among genes diﬀerentially expressed according to genotype
and treatment, respectively. Eighteen of these GO categories
were directly related to neurogenesis (Table 2 in bold).
We then analyzed the expression data focusing on genes
of interest such as the expressed genes that are in three
copies in Ts65Dn mice (3N genes, n = 56) and immediate
early genes (IEGs, n = 16) which are involved in active
memorization processes, and the product of which was
shown to be increased by α5IA treatment in a previous study
[35].
3.2. Gene Expression Changes of 3N Genes after α5IA Treat-
ment. PCA on the 56 3N genes expressed in hippocampus
showed a partial segregation between euploid and Ts65Dn
mice (Figure 3). Expression levels of 3N genes were signif-
icantly diﬀerent in Ts65Dn mice as compared to euploid
mice (t-test P<. 05) with a mean ratio of 1.13 and
1.10 between ts65Dn and euploid mice under vehicle or
α5IA treatment, respectively, suggesting a global increase of
expression of three-copy genes. ANOVA with two factors
(genotype and treatment) speciﬁcally on 3N genes revealed
an eﬀect of genotype on 6 genes that represented 10.71%
of the total number of expressed triplicate genes (56):
Gart, Ifnar-2, Kcnj6, Itsn1, Hlcs,a n dSod1 (Table 1). The
mean expression ratio Ts65Dn/Euploid for these 6 three-
copy genes was found to be 1.22 (t12 = 3.49; P = .0045).
In addition, we found that α5IA treatment impacted on
the expression levels of 3 three-copy genes (App, Kcnj6,
and Sod1). Interactions between genotype and treatment
were signiﬁcant for 5 genes (Cbr1, Gabpa, 4931408A02Rik,
Hmngn1, and Pcp4). Among diﬀerentially expressed genes,
there was no signiﬁcant enrichment of 3N genes. However,
a strong tendency to overrepresentation of three-copy genes
modulated by the genotype factor in comparison to the
overall distribution was observed (chi-square: P = .057;
Table 1).
Among these genes modulated by the genotype factor,
our attention was particularly drawn to the Sod1 gene
whose role in DS was largely demonstrated [38, 39]. In
order to conﬁrm the microarray results, QPCR analysis was
p e r f o r m e do nR N A sf r o m1 3m i c e( 3 - 4p e rg r o u p )u s e df o r
microarray and on RNAs from onther 8 mice (2 per group).
Two-way ANOVA analysis on Sod1 gene showed a treatment
by genotype interaction eﬀect (F1,17 = 16.77; P<. 00005;
Figure 4). Sod1 expression level of vehicle-treated Ts65Dn
mice increased in comparison to vehicle-treated miceAdvances in Pharmacological Sciences 5
Table 2: Analysis of GO categories among the genes diﬀerentially
expressed in the hippocampus of Ts65Dn mice after α5IA and
behavioral stimulation. In bold GO categories related to neuroge-
nesis processes.
GO term Description P value
Enrichment analysis of GO biological processes associated with
genotype
GO:0051272 Positive regulation of cellular
component movement 2.93E−4
GO:0007216 Metabotropicglutamate receptor
signalingpathway 2.96E−4
GO:0032879 Regulation of localization 3.3E −4
GO:0016265 Death 3.55E−4
GO:0009798 Axis speciﬁcation 3.58E−4
GO:0006414 Translational elongation 3.77E−4
GO:0030335 Positive regulation of cell migration 4.21E−4
GO:2000147 Positive regulation of cell motility 4.21E−4
GO:0008219 Cell death 4.49E−4
GO:0065008 Regulation of biological quality 4.66E−4
GO:0012501 Programmedcell death 5.3E −4
GO:0008624 Inductionofapoptosisby
extracellular signals 5.44E−4
GO:0040017 Positive regulation of locomotion 7.32E−4
GO:0008283 Cell proliferation 7.77E−4
GO:0000578 Embryonic axis speciﬁcation 7.96E−4
GO:0006916 Antiapoptosis 8.14E−4
GO:0007049 Cell cycle 9.3E −4
Enrichment analysis of GO biological processes associated with
α5IA treatment
GO:0046883 Regulation of hormone secretion 4.35E−5
GO:0030335 Positive regulation of cell migration 4.89E−5
GO:2000147 Positive regulation of cell motility 4.89E−5
GO:0040017 Positive regulation of locomotion 9.19E−5
GO:0051272 Positive regulation of cellular
component movement 1.04E−4
GO:0048869 Cellular developmental process 1.49E−4
GO:0007176 Regulation of epidermal growth
factor receptor activity 3.38E−4
GO:0040008 Regulation of growth 5.16E−4
GO:0051270 Regulation of cellular component
movement 5.9E −4
GO:0000302 Responseto reactive oxygen species 5.98E−4
GO:0030334 Regulation of cell migration 6.81E−4
GO:0048519 Negative regulation of biological
process 7.57E−4
GO:0009888 Tissuedevelopment 8.46E−4
GO:0006012 Galactose metabolic process 9.12E−4
GO:0009896 Positive regulation of catabolic process 9.15E−4
GO:0030154 Cell diﬀerentiation 9.24E−4
GO:2000145 Regulation of cell motility 9.33E−4
GO:0035413 Positive regulation of catenin import
into nucleus 9.67E−4
GO:0031331 Positive regulation of cellular catabolic
process 9.98E−4
(F1,17 = 7.01; P<. 05) with a mean ratio of 1.27 (Figure 4).
Treatment reduced the level of Sod1 expression in α5IA-
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Figure 3: PCA on three-copy genes from Ts65Dn mice measured
on microarrays. The ﬁrst two principal components discriminated
between euploid and Ts65Dn mice.
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Figure 4: QPCR expression level of Sod1 gene in euploid and
Ts65Dn mice after chronic treatment with vehicle or α5IA. ∗P<
.05, ∗∗P<. 01, and two-way ANOVA with Fisher’s post hoc
comparisons.
treated Ts65Dn mice (F1,17 = 14.43; P<. 01). Thus,
Sod1 expression in Ts65Dn mice under α5IA treatment
was similar to vehicle-treated euploid mice, suggesting that
chronic treatment with α5IA allowed Sod1 to return to
a physiological level of expression in the hippocampus of
Ts65Dn mice.6 Advances in Pharmacological Sciences
3.3. Gene Expression Changes of IEGs Genes after α5IA Treat-
ment. PCA on the 16 IEGs expressed in the hippocampus
showed a total separation between euploid and Ts65Dn mice
but also a partial segregation as a function of treatment
(Figure 5). Two-way ANOVA on these 16 IEGs revealed an
eﬀect of genotype (euploid versus Ts65Dn) on 5 genes (Bdnf,
Cox2,Homer1,RGS2,andArc),aneﬀectoftreatment(vehicle
versus α5IA 5mg/kg) on 3 genes (c-Fos, Egr2, and Bdnf),
and a genotype by treatment interaction eﬀect on one gene
(Bdnf). Among the diﬀerentially expressed genes, there was
a signiﬁcant enrichment of IEGs modulated by genotype
and treatment (chi-square: genotype P<. 001, chi-square:
treatment P<. 05) supporting an eﬀect of genotype and
treatment on IEGs expression levels (Table 1).
We selected 4 IEGs classically described as expressed
during behavioral stimulation: Arc, Homer1, c-Fos, and
EGR2 for validation using QPCR analysis on 21 samples
(5-6 per group), 8 of which were not used in the microarray
experiments (Figure 6). Two-way ANOVA analysis with
within-subjects design on IEGs expression showed genotype
(F1,16 = 7.90; P<. 05), treatment (F1,16 = 11.72; P<. 01), and
gene (F4,64 = 91.66; P<. 001) eﬀects. The expression level
of IEGs was increased in euploid mice (treated or not with
α5IA) as compared to Ts65Dn mice (Fisher’s post hoc test:
P = .012). The mean expression ratio Ts65Dn/euploid for
these 4 genes was found to be 0.82. In contrast, α5IA-treated
mice (euploid or Ts65Dn) showed higher levels of expression
ofIEGsrelativetovehicle-treatedmice(Fisher’sposthoctest:
P = .0034).Themeanexpressionratioα5IA/vehicleforthese
genes was 1.29.
Individual IEGs expression levels were normalized
against the vehicle-treated euploid mice value that corre-
sponds to the physiological level of expression. In euploid
mice, all IEGs increased after α5IA treatment. This increase
was statistically signiﬁcant for c-Fos and Arc genes (one
sample t-test: t4 = 6.44, P = .003, and t4 = 2.89; P =
.04, resp.). In Ts65Dn mice, the basal level of expression
of IEGs was lower as compared to euploids. C-Fos and
Egr2 expression was drastically reduced (one sample t-test:
t3 = 3.62, P = .036, and t3 = 20.38; P = .0003, resp.).
Interestingly, IEGs expression proﬁles were normalized to
euploid mice levels after α5IA treatment. In addition, we
found inverse correlations between the expression levels
of Fos, Egr2, Homer1, and Arc deduced from QPCR and
the mean distance travelled during the ﬁrst three training
sessions of the MWM (−0.645 <r<−0.494; Figure 7).
4. Discussion
We have previously shown that treatment with α5IA alle-
viates learning and memory deﬁcits of Ts65Dn mice [35]
We also demonstrated that α5IA increased the expression
of the IEG product Fos in speciﬁc brain regions involved
in learning and memory following cognitive stimulation.
Importantly, following α5IA administration, both genotypes
were observed to display signiﬁcant and comparable Fos
induction.Thispotentiationofbrainactivitymighttherefore
be the substratum of the general promnesiant eﬀects of α5IA
Euploids vehicle Ts65Dn vehicle
Euploids α5IA Ts65Dn α5IA
52.8
42.3
31.7
21.1
10.6
−10.6
−21.1
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−42.3
−31.7
18.3 −18.3 36.6 −36.65 5 −55 73.3 −73.3 91.6 −91.6
Euploids
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Ts65Dn
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Euploids
vehicle
Ts65Dn Euploids
Vehicle
Treated
Figure 5: PCA on IEGs expression measured on microarrays. The
ﬁrst principal component fully discriminated euploid and Ts65Dn
mice. The second principal component partially discriminated
vehicle- and α5IA-treated mice.
independently of the disease status. In order to gain more
insightintomechanismsofthegeneralpromnesianteﬀectsas
well as the rescuing eﬀects in Ts65Dn mice, we studied gene
expression regulation networks in mice trained in the MWM
task. During this continuous training episode, mice received
daily injections of α5IA (5mg/kg) for a total of 12 days. Gene
expression was then measured using DNA microarrays from
hippocampal RNA extracts obtained 30min after the last
training session.
4.1. Hippocampal Gene Expression Networks Regulated by
α5IA in Control Euploid Mice
4.1.1. Eﬀects on HSA21 Genes. Microarray and QPCR anal-
ysis on the expression of genes from the region of mouse
chromosome 16 which is triplicated in Ts65Dn mice and is
orthologous to human chromosome 21 (HSA21) genes did
not reveal any eﬀect of chronic treatment with α5IA. These
results suggest that genes from this triplicated region are
not interfering with the activity of α5IA and hence do not
modify the α5 subunit-containing GABA-A-benzodiazepine
receptors or their signaling pathways.
4.1.2. Eﬀects on IEGs Expression during Memory Processes.
Followingmemorystimulation,chronictreatmentwithα5IA
enhanced IEG activation in euploid mice. It is likely that
higher IEG transcripts following α5IA treatment will result
in an increase of IEG protein products (e.g., Fos protein)Advances in Pharmacological Sciences 7
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Figure 6: QPCR expression level of selected IEGs. (a) Mean cumulated expression levels of ﬁve selected IEGs in euploid and Ts65Dn mice;
(b) eﬀect of α5IA treatment on the mean level of expression of ﬁve selected IEGs; (c) expression of c-Fos, Egr2, Bdnf, Homer-1, and Arc in the
four genotype and treatment experimental groups. ∗P<. 05, two-way ANOVA with Fisher’s post hoc comparisons; #P<. 05, ###P<. 001,
and one-sample t-test.
as conﬁrmed in our previous study [35], while without
behavioral stimulation, α5IA did not increase the IEG
product Fos (data not shown). These results suggest a
state dependency (cognitive stimulation) of the eﬀects of
α5IA on IEG expression. IEG expression regulation after
α5IA treatment following behavioral stimulation could be a
contributing factor for both the general promnesiant activity
of α5IA and its rescuing eﬀect in Ts65Dn mice alongside
signaling cascades that are critical for memory consolidation
and cognition.8 Advances in Pharmacological Sciences
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Figure 7: Correlation between IEGs expression levels and behavioral performances. Expression levels of IEGs were negatively correlated
to the mean distance travelled during MWM testing (−0.645 <r<−0.494, Pearson correlation) underlining a tight relationship between
learning proﬁciency and IEGs activation.
4.2. Hippocampal Gene Expression Networks Regulated by
α5IA in Ts65Dn Mice
4.2.1. Eﬀects on HSA21 Genes
Gene Expression Diﬀerences between Ts65Dn and Euploid
Hippocampi. Of the 108 HSA21 genes present on the
microarray and expressed in the hippocampus, only 6 were
diﬀerentially expressed between Ts65Dn and euploid mice:
Gart, Ifnar-2, Kcnj6, Itsn1, Hlcs and, Sod1. To our knowledge,
this is the ﬁrst time that gene expression proﬁles have
been established in the hippocampus of adult Ts65Dn mice.
We focused our attention on the Sod1 gene which has
been extensively studied in DS and conﬁrmed our results
using QPCR. LTP deﬁcits observed in Ts65Dn [8]c o u l db e
due to overexpression and thus increased activity of Sod1
in the hippocampus since overexpression of Sod1 gene in
transgenic mice is suﬃc i e n tt oi m p a i rL T P[ 40]. Increased
level of Sod1 has also been shown to enhance the sensitivity
to degeneration and apoptosis leading to a reduction of
hippocampal neuronal progenitors [41]. This could explain
enrichment for numerous GO categories related to neuro-
genesis among the genes diﬀerentially expressed between
Ts65Dn and euploids. Such eﬀects on neurogenesis-related
genes may contribute to the memory deﬁcits observed in
Ts65Dn mice [42] and also in humans with memory dys-
function [43]. Since Sod1 a n dI E G se x p r e s s i o n sa r ei n v e r s e l y
modulated in Ts65Dn mice as compared to euploids before
and after treatment, it could also be speculated that Sod1
and IEGs are functionally regulated, IEGs inhibiting Sod1
expression and conversely increased Sod1 levels decreasing
IEGs after behavioral stimulation.
Chronic Treatment with α5IA Restores the Expression of
Sod1in Ts65Dn Mice to Normal Physiological Levels. ChronicAdvances in Pharmacological Sciences 9
treatment of Ts65Dn mice with α5IA normalized the level
of expression of Sod1 in the hippocampus. Although the
exact mechanisms responsible for this eﬀect are unclear,
we can postulate that chronic treatment with α5IA could
alleviate cognitive deﬁcits at least partly through the nor-
malization of Sod1 expression in the hippocampus. Since
Sod1 overexpression impairs hippocampal neurogenesis and
long-term synaptic plasticity, α5IA could reverse these
deleteriouseﬀectsbydecreasingtheexpressionlevelsofSod1.
Stimulating or restoring neurogenesis might thus participate
intherecoveryofcognitivefunctionsofTs65Dnmice,assug-
gested also by enrichment of GO categories associated with
proliferation and cell death among diﬀerentially expressed
genes.
4.2.2. Eﬀects on IEGs Expression
Reduction of IEG Activation Pattern in Ts65Dn Mice. It is
known that IEGs play a key role in learning and memory
mechanisms which are deﬁcient in Ts65Dn mice. Indeed,
long-term memory requires activation of speciﬁc IEGs [44].
Neuronal IEGs mostly code for transcription factors, growth
factors, cytoskeletal proteins, metabolic enzymes, or proteins
involved in signal transduction [45]. Memorization of new
information requires the establishment of a pattern of IEGs
expression. It has been shown that age-related memory
deﬁcits in rats result in an overall decrease in the expression
of IEG in the hippocampus, particularly Homer-1, Arc,a n d
diﬀerent members of EGR family [46]. After behavioral
stimulation in the MWM task, we found, using microarray
andQPCR,asigniﬁcantreductionintheoveralllevelofIEGs
in Ts65Dn mice as compared to euploids. This reduction was
observed in particular for c-Fos and Egr2.F o rHomer-1,a n d
Arc, decreased expression in Ts65Dn mice was just below the
level of signiﬁcance. This could be due to diﬀerences in the
kinetics of waves of expression of these particular IEGs [44].
ChronicTreatmentofTs65DnMicewithα5IARestoresNormal
IEG Activation Pattern. Ts65Dn mice treated chronically
with α5IA showed normalized levels of activation of IEG
following memory stimulation, particularly c-Fos, Egr2,
Homer-1 and Arc that could be related to the recovery of
MWM performance deﬁcits observed in the present study
a n dd e m o n s t r a t e dp r e v i o u s l y[ 35]. Normalization of the
activation proﬁle of IEG following behavioral stimulation
could thus be responsible for the rescuing eﬀects of α5IA
observed in Ts65Dn mice. The close relationship between
IEGs expression levels and cognitive performances was
indeedsuggestedbythesigniﬁcantinversecorrelationsfound
between the expression levels of Fos, Egr2, Homer1 and Arc
and performances in the MWM task. In addition, α5IA
treatment was shown to restore Ts65Dn mice performances
in the MWM task and to normalize the expression levels of
c-Fos, Egr2, Homer-1,a n dArc.
4.3. General Promnesiant and Rescuing Eﬀects of α5IA. The
general α5IA promnesiant eﬀect observed in euploid and
Ts65Dn mice could be explained by the acute phar-
macological action of the drug directly on α5G A B A -
A-benzodiazepine receptors. Indeed, α5 inverse agonists
decrease GABAergic transmission and promote the excitabil-
ity of postsynaptic neurons in rodents [28–32]. The pre-
viously described increase of Fos protein immunoreactiv-
ity after short-term memory stimulation combined with
α5IA acute treatment could thus be the consequence of
immediate release of GABA inhibition [35]. Following
repetitive cognitive stimulations as in the MWM task that
involves hippocampus-dependent memory, we evidenced
IEGs activation deﬁcits in the hippocampus of Ts65Dn mice
that were rescued after chronic α5IA treatment. However, we
cannot exclude that a single injection of α5IA would have a
similar eﬀect on IEGs expression levels. It thus appears that
therescuingeﬀectsofα5IAonlong-termmemoriesaremore
likely the consequence of hippocampal IEGs expression nor-
malization than the long term eﬀect of repetitive GABAergic
modulations. In addition, as mentioned above, it is likely
thatthenormalizationofSod1overexpression by α5IAisalso
important to promote cognitive rescuing.
5. Conclusions
We have identiﬁed genomic changes related to chronic
treatment with α5IA, an α5-selective GABA-A receptor
inverse agonist. Under physiological conditions in which
α5IA has been shown to be promnesiant, increase of IEGs
activation has been observed and in particular of c-Fos and
Arc genes. This increase of activation could allow a more
eﬃcient storage of information during memory process.
Under pathological conditions such as DS in which
deﬁcits in learning and memory have been described, we
were able to demonstrate an eﬀect of chronic treatment
with α5IA at the level of expression of diﬀerent genes
in Ts65Dn mice. Indeed, chronic administration of α5IA
restored a normal level of Sod1 e x p r e s s i o nw h i c hi si n v o l v e d
in hippocampal neurogenesis and LTP. In addition, chronic
treatment with α5IA normalized the pattern of IEGs acti-
v a t i o nt h a ti sd e ﬁ c i e n ti nT s 6 5 D nm i c e .T h e s eg e n o m i c
changes observed after chronic treatment with α5IA could
be responsible for the restoration of learning and memory
functions in Ts65Dn mice.
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